The effect of ketoconazole on whole blood and skin ciclosporin concentrations in dogs

Veterinary Dermatology

Volumn 24, Issue 1, 2013, Pages

  Gray, Laura L ^a   Hillier, Andrew ^a   Cole, Lynette K ^a   Rajala Schultz, Päivi J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE;

ANIMAL; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG INTERACTION; METABOLISM; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN;

ANIMALS; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; CYCLOSPORINE; DOGS; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; PILOT PROJECTS; SKIN;

ANIMALIA; CANIS FAMILIARIS;

EID: 84872717592     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2012.01064.x     Document Type: Article

References (41)

1. ® (Cyclosporine capsules, USP) modified [package insert]. Greensboro, NC: Novartis Animal Health, US, Inc., 2008. NADA 141-218.
2. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47: 119-125.
3. Ferraccioli GF, Tomietto P, De Santis M. Rationale for Tcell inhibition by cyclosporinA in major autoimmune diseases. Ann N Y Acad Sci 2005; 1051: 658-665.
4. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006; 17: 3-16.
5. Steffan J, Alexander D, Brovedani F et al. Comparison of cyclosporineA with methylprednisolone for treatment of canine atopic dermatitis: a parallel, blinded, randomized controlled trial. Vet Dermatol 2003; 14: 11-22.
6. Olivry T, Steffan J, Fisch RD et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002; 221: 370-377.
7. Radowicz SN, Power HT. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Vet Dermatol 2005; 16: 81-86.
8. Kuroha M, Kuze Y, Shimoda M et al. In vitro characterization of the inhibitory effects of ketoconazole on metabolic activities of cytochrome P-450 in canine hepatic microsomes. Am J Vet Res 2002; 63: 900-905.
9. Aidasani D, Zaya MJ, Malpas PB et al. In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. Drug Metab Dispos 2008; 36: 1512-1518.
10. Daigle JC, Hosgood G, Foil CS et al. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am J Vet Res 2001; 62: 1046-1050.
11. Radwanski NE, Cerundolo R, Shofer FS et al. Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. Am J Vet Res 2011; 72: 687-693.
12. Amatori FM, Meucci V, Giusiani M et al. Effects of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 2004; 154: 180-181.
13. D'mello A, Venkataramanan R, Satake M et al. Pharmacokinteics of the cyclosproine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 1989; 64: 441-454.
14. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998; 27: 64-68.
15. Mouatt JG. Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Aust Vet J 2002; 80: 207-211.
16. Patricelli AJ, Hardie RJ, McAnulty JF. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 2002; 220: 1009-1016.
17. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporineA and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004; 45: 238-243.
18. Myre SA, Schoeder TJ, Grund VR et al. Critical ketoconazole dosage range for ciclosporin clearance inhibition in the dog. Pharmacology 1991; 43: 233-241.
19. Fisher GJ, Duell EA, Nickoloff BJ et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol 1988; 91: 142-146.
20. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. New Eng J Med 1991; 324: 277-284.
21. Steffan J, Maurer M, Rohlfs A. Cyclosporine concentration in the skin following oral administration, in Proceedings. 18th Ann ESVD-ECVD Cong 2002; 222.
22. Yu A. Dermatologic pearls: what's new in the diagnosis and treatment of skin disease, in Proceedings. 80th Annu West Vet Conf, V78, 2008, Available at: http://www.vin.com/Members/proceedings/Proceedings.plx?CID=WVC2008&Category=3183&PID=19908&O=VIN. Accessed April 7, 2012.
23. Ihrke P. The management of canine atopic dermatitis, in Proceedings. Can Med Symp 2009, Available at: http://www.vin.com/Members/Proceedings/Proceedings.plx?CID=UCDCMC2009&Category=&PID=32508&O=VIN. Accessed April 7, 2012.
24. MacDonald J. Treating the atopic dog: options to keep the pet owner happy, in Proceedings. Atlantic Coast Vet Conf 2007, Available at: http://www.vin.com/Members/Proceedings/Proceedings.plx?CID=ACVC2007&Category=&PID=19052&O=VIN. Accessed April 7, 2012.
25. Merchant S. Diagnosis and management of the pruitic dog, in Proceedings. Atlantic Coast Vet Conf 2009, Available at: http://www.vin.com/Members/Proceedings/Proceedings.plx?CID=acvc2009&PID=pr53372&O=VIN. Accessed April 7, 2012.
26. Marsella R. Medical management of pruritus: non-specifictherapy for management of the pruritic dog or cat, in Proceedings. Atlantic Coast Vet Conf 2008, Available at: http://www.vin.com/Members/proceedings/Proceedings.plx?CID=ACVC2008&Category=&PID=25941&O=VIN. Accessed April 7, 2012.
27. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218.
28. Steffan J, Strehlau G, Maurer M et al. CyclosporinA pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004; 27: 231-238.
29. Trissel LA. Trissel's stability of compounded formulations. In: Trissel's Stability of Compounded Formulations. 2nd edn. Washington, DC: American Pharmacists Association, 2000;206-207.
30. Christians U, Jacobsen W, Serkova N et al. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatog B Biomed Sci Appl 2000; 748: 41-53.
31. Levy G, Burra P, Cavallari A et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1. Transplantation 2002; 73: 953-959.
32. Pollard SG. Pharmacologic monitoring and outcomes of cyclosporine. Transplant Proc 2004; 36: S404-S407.
33. Mayer UK, Glos K, Schmid M et al. Adverse effects of ketoconazole in dogs - a retrospective study. Vet Dermatol 2008; 19: 199-208.
34. Niederberger W. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983; 15: 2419-2421.
35. Wagner O, Shcreier E, Heitz F et al. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Am Soc Pharmacol Exp Ther 1987; 15: 377-385.
36. Pollard SG, Nashan B, Johnston A et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporinA. Clin Ther 2003; 25: 1654-1669.
37. Cattaneo D, Ruggenenti P, Baldelli S et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 2009; 20: 1404-1415.
38. Zhu HJ, Yuan SH, Fang Y et al. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J 2011; 11: 237-246.
39. Anglicheau D. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422-433.
40. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004; 27: 257-264.
41. Culmsee K, Gruber AD, von Samson-Himmelstjerna G et al. Quantification of MDR-1 gene expression in canine tissues by real-time reverse transcription quantitative polymerase chain reaction. Res Vet Sci 2004; 77: 223-229.